Bausch Health Gets FDA Approval for Acne Treatment Cabtreo
2023年10月21日 - 7:05AM
Dow Jones News
By Ben Glickman
Bausch Health Cos. has received approval from the Food and Drug
Administration for Cabtreo, its topical gel for acne.
The Laval, Quebec-based pharmaceutical company said the
treatment, which combines clindamycin phosphate, adapalene and
benzoyl peroxide, is expected to become available in the first
quarter of 2024.
The approved new drug application allows for the use of Cabtreo
in treating acne vulgaris in patients 12 years and older.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 20, 2023 17:50 ET (21:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Bausch Health Companies (TSX:BHC)
過去 株価チャート
から 4 2024 まで 5 2024
Bausch Health Companies (TSX:BHC)
過去 株価チャート
から 5 2023 まで 5 2024
